4//SEC Filing
Lees-Rolfe Garth 4
Accession 0000950170-25-003130
CIK 0001750149other
Filed
Jan 6, 7:00 PM ET
Accepted
Jan 7, 6:43 PM ET
Size
10.1 KB
Accession
0000950170-25-003130
Insider Transaction Report
Form 4
Lees-Rolfe Garth
Chief Financial Officer
Transactions
- Award
Stock Option (Right to Buy)
2025-01-03+432,853→ 432,853 totalExercise: $1.58Exp: 2035-01-03→ Common Stock (432,853 underlying) - Award
Stock Option (Right to Buy)
2025-01-03+470,861→ 470,861 totalExercise: $1.26Exp: 2035-01-03→ Common Stock (470,861 underlying) - Award
Stock Option (Right to Buy)
2025-01-03+235,383→ 235,383 totalExercise: $1.45Exp: 2035-01-03→ Common Stock (235,383 underlying)
Footnotes (3)
- [F1]The options vested and became exercisable on October 9, 2024.
- [F2]The options will vest and become exercisable upon the expiration of the exercise period of the Issuer's Series A-1 Warrants in an amount proportional to the actual number of Series A-1 Warrants exercised, subject to the Reporting Person's continuous service to the Issuer through such date. Any options that do not become vested shall be automatically forfeited without consideration in respect thereof.
- [F3]The options will vest and become exercisable upon the expiration of the exercise period of the Issuer's Series B-1 Warrants in an amount proportional to the actual number of Series B-1 Warrants exercised, subject to the Reporting Person's continuous service to the Issuer through such date. Any options that do not become vested shall be automatically forfeited without consideration in respect thereof.
Documents
Issuer
Inhibikase Therapeutics, Inc.
CIK 0001750149
Entity typeother
Related Parties
1- filerCIK 0002017374
Filing Metadata
- Form type
- 4
- Filed
- Jan 6, 7:00 PM ET
- Accepted
- Jan 7, 6:43 PM ET
- Size
- 10.1 KB